These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29546355)

  • 1. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
    Lu K; Wang X; Chen Y; Liang D; Luo H; Long L; Hu Z; Bao J
    Acta Biochim Biophys Sin (Shanghai); 2018 May; 50(5):456-464. PubMed ID: 29546355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen synthase kinase 3β promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
    Mai W; Kong L; Yu H; Bao J; Song C; Qu G
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 33969873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
    Pardhi T; Vasu K
    J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
    Zhu J; Wu Y; Xu L; Jin J
    Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
    Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
    J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico screening and identification of potential GSK3β inhibitors.
    Daggupati T; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Aug; 38(4):279-289. PubMed ID: 29947280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
    Benghanem S; Mesli F; Fatima Zohra HA; Nacereddine C; Hadjer C; Abdellatif M
    J Biomol Struct Dyn; 2024 Sep; 42(14):7091-7106. PubMed ID: 37498130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the bindings of a class of inhibitors with GSK3β kinase using thermodynamic integration MD simulation and kinase assay.
    Hsu CJ; Hsu WC; Lee DJ; Liu AL; Chang CM; Shih HJ; Huang WH; Lee-Chen GJ; Hsieh-Li HM; Lee GC; Sun YC
    Chem Biol Drug Des; 2017 Aug; 90(2):272-281. PubMed ID: 28127860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis and Biological Evaluation of 7-Chloro-9
    Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.
    Shimozaki S; Yamamoto N; Domoto T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Miwa S; Igarashi K; Kato T; Aoki Y; Higuchi T; Hirose M; Hoffman RM; Minamoto T; Tsuchiya H
    Oncotarget; 2016 Nov; 7(47):77038-77051. PubMed ID: 27780915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
    Zhao S; Zhu J; Xu L; Jin J
    Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
    Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
    Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying potential Alzheimer's disease therapeutics through GSK-3β inhibition: A molecular docking and dynamics approach.
    Mohammadi Y; Emadi R; Maddahi A; Shirdel S; Morowvat MH
    Comput Biol Chem; 2024 Aug; 111():108095. PubMed ID: 38805865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
    Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
    J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β.
    Yang Z; Liu H; Pan B; He F; Pan Z
    Org Biomol Chem; 2018 Jun; 16(22):4127-4140. PubMed ID: 29781013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.
    Wan D; Han X; Zhang C; Zhang Y; Ma Y; Wang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1179-1186. PubMed ID: 35818168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Fragment-Based de Novo Design to the Discovery of Selective Picomolar Inhibitors of Glycogen Synthase Kinase-3 Beta.
    Park H; Shin Y; Kim J; Hong S
    J Med Chem; 2016 Oct; 59(19):9018-9034. PubMed ID: 27676184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Glycogen Synthase Kinase Inhibitors That Regulate Cytochrome P450 Expression in Primary Human Hepatocytes by Activation of β-Catenin, Aryl Hydrocarbon Receptor and Pregnane X Receptor Signaling.
    Briolotti P; Chaloin L; Balaguer P; Da Silva F; Tománková V; Pascussi JM; Duret C; Fabre JM; Ramos J; Klieber S; Maurel P; Daujat-Chavanieu M; Gerbal-Chaloin S
    Toxicol Sci; 2015 Nov; 148(1):261-75. PubMed ID: 26259606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
    Gao Y; Ye DY; Zhou WC; Chu Y
    Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
    Arfeen M; Patel R; Khan T; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.